Patient Demographics and Characteristics of Infection with Carbapenem-Resistant Acinetobacter baumannii in a Teaching Hospital from the United States


A characterization of the clinical demographic features of patients with infection caused Acinetobacter baumannii, and the antibiotyping of the isolates recovered from these patients was undertaken, with a special reference to carbapenem-resistant variants, and their risk factors. This study was conducted retrospectively from January 2010 to March 2011 at a 616-bed tertiary care university hospital. Sixty-four patients were identified. Clinical and microbiological data were analyzed for risk factors and demographic features to derive relative risk and odds ratio. We identified 100 A. baumannii from 64 patients during 15 months period. Significant risk factors were working age (18 - 60 years), male gender, hospital stay (>1 week but <1 month), prior hospitalization, in a progressive care nursing units, respiratory/mechanical ventilation, polymicrobial infections and prior antibiotic therapy. Methicillin-resistant staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Klebsiella pneumoniae were the significant co-infecting agents. The antibiogram demonstrated multidrug resistance in a majority of the isolates. Relative risk associated with ventilator, diabetes, and surgery was higher in repeat isolates than in first isolates and were multidrug resistant. Repeat isolates were more resistant that the first isolates to most anti-acinetobacter agents, but the overall crude mortality was not significant during this study period, and couldn’t correlated to the choice of treatment. In conclusion, a resistance against all clinically used carbapenems, and colistin is rapidly increasing in repeat isolates of A. baumannii; leaves narrow therapeutic options to treat multidrug-resistant and pandrug-resistant A. baumannii infection. For the first time we report rising incidence of colistin resistance by 20 percent in repeat isolates, and is worrisome for healthcare centers. A combination therapy should be adopted to treat such infection to avoid the emergence of colistin-resistant phenotypes in the United States.

Share and Cite:

N. D. Vaze, C. L. Emery, R. J. Hamilton, A. D. Brooks and S. G. Joshi, "Patient Demographics and Characteristics of Infection with Carbapenem-Resistant Acinetobacter baumannii in a Teaching Hospital from the United States," Advances in Infectious Diseases, Vol. 3 No. 1, 2013, pp. 10-16. doi: 10.4236/aid.2013.31002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. Turkoglu, E. Mirza, O. G. Tunccan, et al., “Acinetobacter baumannii Infection in Patients with Hematologic Malignancies in Intensive Care Unit: Risk Factors and Impact on Mortality,” Journal of Critical Care, Vol. 26, No. 5, 2011, pp. 460-467. doi:10.1016/j.jcrc.2011.04.007
[2] M. Shanthi and U. Sekar, “Multi-Drug Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Infections among Hospitalized Patients: Risk Factors and Outcomes,” Journal of the Association of Physicians of India, Vol. 57, 2009. pp. 636-645.
[3] H. Wisplinghoff, T. Paulus, M. Lugenheim et al., “Nosocomial Bloodstream Infections Due to Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis in the United States,” Journal of Infection, Vol. 64, No. 3, 2012, pp. 282-290. doi:10.1016/j.jinf.2011.12.008
[4] T. J. Whitman, S. S. Qasba, J. G. Timpone, et al., “Occupational Transmission of Acinetobacter baumannii from a United States Serviceman Wounded in Iraq to a Health Care Worker,” Clinical Infectious Diseases, Vol. 47, No. 4, 2008, pp. 439-443. doi:10.1086/589247
[5] M. Dizbay, O. G. Tunccan, B. E. Sezer, et al., “Nosocomial Imipenem-Resistant Acinetobacter baumannii Infections: Epidemiology and Risk Factors,” Scandanavian Journal of Infectious Diseases, Vol. 42, No. 10, 2010, pp. 741-746. doi:10.3109/00365548.2010.489568
[6] J. Gomez, E. Simarro, V. Banos, et al., “Six-Year Prospective Study of Risk and Prognostic Factors in Patients with Nosocomial Sepsis Caused by Acinetobacter baumannii,” European Journal Clinical Microbiology and Infectious Diseases, Vol. 18, No. 5, 1999, pp. 358-361. doi:10.1007/PL00015019
[7] J. Y. Jung, M. S. Park, S. E. Kim, et al., “Risk Factors for Multi-Drug Resistant Acinetobacter baumannii Bacteremia in Patients with Colonization in the Intensive Care Unit,” BMC Infectious Diseases, Vol. 10, 2010, p. 228. doi:10.1186/1471-2334-10-228
[8] S. Yang, H. J. Yoon and M. R. Ki, “Risk Factors for Mortality in Acinetobacter bacteremia,” Brazilianl Journal of Infectious Diseases, Vol. 15, No. 5, 2011, pp. 501-502.
[9] C. G. Prates, A. F. Martins, S. V. Superti, et al., “Risk Factors for 30-Day Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii during an Outbreak in an Intensive Care Unit,” Epidemiology and Infection, Vol. 139, No. 3, 2011, pp. 411-418. doi:10.1017/S0950268810001238
[10] S. G. Joshi, G. M. Litake, M. G. Satpute, et al., “Clinical and Demographic Features of Infection Caused by Acinetobacter Species,” Indian Journal of Medical Sciences, Vol. 60, No. 9, 2006, pp. 351-360. doi:10.4103/0019-5359.27219
[11] M. del Mar Tomas, M. Cartelle, S. Pertega, et al., “Hospital Outbreak Caused by a Carbapenem-Resistant Strain of Acinetobacter baumannii: Patient Prognosis and Risk-Factors for Colonisation and Infection,” Clinical Microbiology and Infection, Vol. 11, No. 7, 2005, pp. 540-546. doi:10.1111/j.1469-0691.2005.01184.x
[12] S. F. Beavers, D. B. Blossom, T. L. Wiemke, et al., “Comparison of Risk Factors for Recovery of Acinetobacter baumannii during Outbreaks at Two Kentucky Hospitals, 2006,” Public Health Reports, Vol. 124, No. 6, 2009, pp. 868-874.
[13] J. M. Cisneros, J. Rodriguez-Bano, F. Fernandez-Cuenca, et al., “Risk-Factors for the Acquisition of Imipenem-Resistant Acinetobacter baumannii in Spain: A Nationwide Study,” Clinical Microbiology and Infection, Vol. 11, No. 11, 2005, pp. 874-879. doi:10.1111/j.1469-0691.2005.01256.x
[14] Y. S. Park, H. Lee, K. S. Lee, et al., “Extensively Drug-Resistant Acinetobacter baumannii: Risk Factors for Acquisition and Prevalent OXA-Type Carbapenemases: A Multicentre Study,” International Journal of Antimicrobial Agents, Vol. 36, No. 5, 2010, pp. 430-435. doi:10.1016/j.ijantimicag.2010.06.049
[15] Y. J. Kim, S. I. Kim, Y. R. Kim, et al., “Carbapenem-Resistant Acinetobacter baumannii: Diversity of Resistant Mechanisms and Risk Factors for Infection,” Epidemiology and Infection, Vol. 140, No. 1, 2012, pp. 137-145. doi:10.1017/S0950268811000744
[16] J. Baraibar, H. Correa, D. Mariscal, et al., “Risk Factors for Infection by Acinetobacter baumannii in Intubated Patients with Nosocomial Pneumonia,” Chest, Vol. 112, No. 4, 1997, pp. 1050-1054. doi:10.1378/chest.112.4.1050
[17] T. H. Wong, B. H. Tan, M. L. Ling, et al., “Multi-Resistant Acinetobacter baumannii on a Burns Unit: Clinical Risk Factors and Prognosis,” Burns, Vol. 28, No. 4, 2002, pp. 349-357. doi:10.1016/S0305-4179(02)00012-8
[18] W. H. Sheng, C. H. Liao, T. L. Lauderdale, et al., “A Multicenter Study of Risk Factors and Outcome of Hospitalized Patients with Infections Due to Carbapenem-Resistant Acinetobacter baumannii,” International Journal of Infectious Diseases, Vol. 14, No. 9, 2010, pp. 764-769. doi:10.1016/j.ijid.2010.02.2254
[19] M. M. D’Andrea, C. Venturelli, T. Giani, et al., “Persistent Carriage and Infection by Multidrug-Resistant Escherichia Coli ST405 Producing NDM-1 Carbapenemase: Report on the First Italian Cases,” Journal of Clinical Microbiology, Vol. 49, No. 7, 2011, pp. 2755-2758. doi:10.1128/JCM.00016-11
[20] R. Jayaraman, “Hypermutation and Stress Adaptation in Bacteria,” Journal of Genetics, Vol. 90, No. 2, 2011, pp. 383-391. doi:10.1007/s12041-011-0086-6
[21] J. D. Pitout, K. B. Laupland, D. L. Church, et al., “Virulence Factors of Escherichia Coli Isolates that Produce CTX-M-Type Extended-Spectrum Beta-Lactamases,” Antimicrobial Agents and Chemotherapy, Vol. 49, No. 11, 2005, pp. 4667-4670. doi:10.1128/AAC.49.11.4667-4670.2005
[22] J. Rodriguez-Bano, J. M. Cisneros, F. Fernandez-Cuenca, et al., “Clinical Features and Epidemiology of Acinetobacter baumannii Colonization and Infection in Spanish Hospitals,” Infect Control and Hospital Epidemiology, Vol. 25, No. 10, 2004, pp. 819-824. doi:10.1086/502302
[23] S. M. Poutanen, M. Louie and A. E. Simor, “Risk Factors, Clinical Features and Outcome of Acinetobacter bacteremia in Adults,” European Journal of Clinical Microbiology and Infectious Diseases, Vol. 16, No. 10, 1997, pp. 737-740. doi:10.1007/BF01709254
[24] R. M. Mera, L. A. Miller, H. Amrine-Madsen, et al., “Acinetobacter baumannii 2002-2008: Increase of Carbapenem-Associated Multiclass Resistance in the United States,” Microbial Drug Resistance, Vol. 16, No. 3, 2010, pp. 209-215. doi:10.1089/mdr.2010.0052
[25] A. Abbo, S. Navon-Venezia, O. Hammer-Muntz, et al., “Multidrug-Resistant Acinetobacter baumannii,” Emerging Infectious Diseases, Vol. 11, No. 1, 2005, pp. 22-29. doi:10.3201/eid1101.040001
[26] G. Baran, A. Erbay, H. Bodur, et al., “Risk Factors for Nosocomial Imipenem-Resistant Acinetobacter baumannii Infections,” International Journal of Infectious Diseases, Vol. 12, No. 1, 2008, pp. 16-21. doi:10.1016/j.ijid.2007.03.005
[27] N. Y. Lee, H. C. Lee, N. Y. Ko, et al., “Clinical and Economic Impact of Multidrug Resistance in Nosocomial Acinetobacter baumannii Bacteremia,” Infection Control and Hospital Epidemiology, Vol. 28, No. 6, 2007, pp. 713-719. doi:10.1086/517954
[28] J. Medina, C. Formento, J. Pontet, et al., “Prospective Study of Risk Factors for Ventilator-Associated Pneumonia Caused by Acinetobacter Species,” Journal of Critical Care, Vol. 22, No. 1, 2007, pp. 18-26. doi:10.1016/j.jcrc.2006.06.010
[29] A. Martinez-Pellus, J. Ruiz Gomez, F. Jaime Sanchez, et al., “[Incidence of Colonization and Infection by Acinetobacter baumannii in an Endemic Seting (ICU). Analysis of Risk Factors by Means of a Surveillance Study],” Enfermedades Infecciosas y Microbiologia Clinica, Vol. 20, No. 5, 2002, pp. 194-199.
[30] H. C. Chang, Y. C. Chen, M. C. Lin, et al., “Mortality Risk Factors in Patients with Acinetobacter baumannii Ventilator: Associated Pneumonia,” Journal of the Formosan Medical Association, Vol. 110, No. 9, 2011, pp. 564-571. doi:10.1016/j.jfma.2011.07.004
[31] P. A. Tilley, and F. J. Roberts, “Bacteremia with Acinetobacter Species: Risk Factors and Prognosis in Different Clinical Settings,” Clinical Infectious Diseases, Vol. 18, No. 6, 1994, pp. 896-900. doi:10.1093/clinids/18.6.896
[32] J. Koprnova, I. Svetlansky, R. Babel’a, et al., “Prospective Study of Antibacterial Susceptibility, Risk Factors and Outcome of 157 Episodes of Acinetobacter baumannii Bacteremia in 1999 in Slovakia,” Scandanavian Journal of Infectious Diseases, Vol. 33, No. 12, 2001, pp. 891-895. doi:10.1080/00365540110076688

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.